SEC 13F Intelligence

Managers / Q4 2024 · view latest →

Artia Global Partners LP

CIK 0001937964 · 1 SE 3RD AVENUE, STE 2120, MIAMI, FL, 33131 · 3057101384

Reported Value
$280M
Q4 2024
Positions
37
Filings on Record
15
2019–present window
Filed
Feb 14, 2025
original filing

Summary

Artia Global Partners LP reported $280M in U.S.-listed holdings across 37 positions for Q4 2024.

Its largest position, SLNOEUR, represents 7.9% of the portfolio.

Compared with Q3 2024, the fund opened 10 new positions and exited 19.

Portfolio Metrics

Turnover
+39.4%
vs prior filed quarter
Top-10 Concentration
+58.0%
share of reported value
Largest Position
+7.9%
Soleno Therapeutics
New / Exited
10 / 19
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $262MQ4 ’22Q1 ’23: $271MQ2 ’23: $290MQ2 ’23Q3 ’23: $241MQ4 ’23: $344MQ4 ’23Q1 ’24: $498MQ2 ’24: $517MQ2 ’24Q3 ’24: $367MQ4 ’24: $280MQ4 ’24Q1 ’25: $395MQ2 ’25: $416MQ2 ’25Q3 ’25: $631MQ4 ’25: $706MQ4 ’25Q1 ’26: $499Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 62.9%ADR: 26.0%Other: 7.8%ETP: 3.2%
  • Common Stock · 62.9% · $176M
  • ADR · 26.0% · $73M
  • Other · 7.8% · $22M
  • ETP · 3.2% · $9M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ACLXGBXARCELLX INCNEW+229.8K229.8K+$18M$18M
SPDR SER TRNEW+100.0K100.0K+$9M$9M
JANXJANUX THERAPEUTICS INCNEW+163.0K163.0K+$9M$9M
RYTMRHYTHM PHARMACEUTICALS INCNEW+50.0K50.0K+$3M$3M
ELVNENLIVEN THERAPEUTICS INCNEW+102.9K102.9K+$2M$2M
VRDNVIRIDIAN THERAPEUTICS INCNEW+100.0K100.0K+$2M$2M
TGTXTG THERAPEUTICS INCNEW+54.5K54.5K+$2M$2M
EWTXEDGEWISE THERAPEUTICS INCNEW+50.0K50.0K+$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2024

33 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SLNOEURSOLENO THERAPEUTICS INChistory →COM7.94%$22M494.4K
2MERUS N VCOM6.97%$20M463.8K
3ITCIEURINTRA-CELLULAR THERAPIES INChistory →COM6.56%$18M219.7K
4ACLXGBXARCELLX INChistory →COMMON STOCK6.30%$18M229.8K
5NVONOVO-NORDISK A Shistory →ADR6.15%$17M200.0K
6NUVLNUVALENT INChistory →COM5.71%$16M204.0K
7PCVXVAXCYTE INChistory →COM4.75%$13M162.3K
8ALNYALNYLAM PHARMACEUTICALS INChistory →COM4.74%$13M56.4K
9AZNNASTRAZENECA PLChistory →SPONSORED ADR4.47%$12M190.8K
10RVMDREVOLUTION MEDICINES INChistory →COM4.44%$12M284.2K
11VRNAVERONA PHARMA PLChistory →SPONSORED ADS4.24%$12M255.3K
12IM8NINSMED INChistory →COM PAR $.014.14%$12M167.9K
13PTGXPROTAGONIST THERAPEUTICS INChistory →COM4.05%$11M293.9K
14JANXJANUX THERAPEUTICS INChistory →COM3.12%$9M163.0K
15ARGXARGENX SEhistory →SPONSORED ADR2.49%$7M11.3K
16NBIXNEUROCRINE BIOSCIENCES INChistory →COM2.20%$6M45.0K
17VKTXVIKING THERAPEUTICS INChistory →COM1.30%$4M90.3K
18RYTMRHYTHM PHARMACEUTICALS INChistory →COM1.00%$3M50.0K
19CRNXCRINETICS PHARMACEUTICALS INCOM0.84%$2M45.8K
20ELVNENLIVEN THERAPEUTICS INCCOM0.83%$2M102.9K
21SWTXUSDSPRINGWORKS THERAPEUTICS INCCOM0.70%$2M53.9K
22VRDNVIRIDIAN THERAPEUTICS INCCOM0.69%$2M100.0K
23TGTXTG THERAPEUTICS INCCOM0.59%$2M54.5K
24EYPTEYEPOINT PHARMACEUTICALS INCCOM NEW0.58%$2M216.7K
25XENEXENON PHARMACEUTICALS INCCOM0.56%$2M40.0K
26MREOMEREO BIOPHARMA GROUP PLCSPON ADS0.53%$1M421.4K
27NEWAMSTERDAM PHARMA COMPANYORDINARY SHARES0.50%$1M54.3K
28260CENTESSA PHARMACEUTICALS PLCSPONSORED ADS0.48%$1M80.4K
29CHARLES RIV LABS INTL INCCOM0.42%$1M6.3K
30TARSTARSUS PHARMACEUTICALS INCCOM0.41%$1M20.8K
31ASCENDIS PHARMA A/SSPONSORED ADR0.37%$1M7.4K
32ANNXANNEXON INCCOM0.32%$883,519172.2K
33TECXTECTONIC THERAPEUTIC INCCOM0.27%$768,73116.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$499M50May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$706M55Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$631M51Nov 14, 2025RESTATEMENTchanges · EDGAR ↗
Q2 2025$416M37Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$395M38May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$280M37Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$367M45Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$517M46Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$498M49May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$344M31Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$241M27Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$290M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$271M36May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$262M25Feb 14, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.